Blood in urine and cancer risk: when to worry and what to do

Blood in the urine is never a finding to dismiss, and the question I am asked most often by referring GPs and by patients is the same: how worried should I be about cancer. This article gives the honest answer based on the evidence and on what I see in clinical practice.

Blood in the urine is a symptom that can never be dismissed without investigation. In a small but meaningful proportion of cases, it is the first sign of a urological cancer. For most patients, the cause turns out to be something less serious: a urinary tract infection, a kidney stone, a benign condition such as IgA nephropathy or thin basement membrane disease, or sometimes nothing identifiable at all. But the only way to know is to investigate, and the structured approach to investigation is well established.

This guide walks through what the cancer risk actually is, who is most at risk, what types of cancer can present this way, what the investigation involves, and what to expect from the process.

The overall risk of finding cancer in patients with visible blood in urine is around 10 to 25 per cent, depending on age and other risk factors. In patients with non-visible haematuria (blood detected only on a urine dipstick or microscopy), the risk is lower, around 1 to 5 per cent. Both figures are high enough to justify systematic investigation. Even the lower figure means that something like 1 in 30 patients with persistent non-visible haematuria will have a cancer found, and missing it has serious consequences.

The cancers most commonly associated with haematuria are bladder cancer, kidney cancer, prostate cancer in men, and rarely cancer of the ureters or renal pelvis. Each has its own pattern of presentation and risk factors.

Bladder cancer is the most common urological cancer presenting with haematuria. The classical pattern is painless visible blood in urine in a patient over 50, often with a history of smoking. Bladder cancer accounts for around 5 per cent of all cancer diagnoses in Ireland and is the seventh most common cancer overall. It is more common in men than women, and the average age at diagnosis is around 70. Strong risk factors include current and former smoking, occupational exposure to certain industrial chemicals (particularly aromatic amines used in dyes, rubber, and leather processing), exposure to certain medications (cyclophosphamide), and a history of pelvic radiation. The cancer typically arises from the urothelium, the lining of the bladder. Most bladder cancers are diagnosed at a stage where they are confined to the inner layers of the bladder (non-muscle-invasive disease) and have a good prognosis. Around 25 per cent are diagnosed at a more advanced stage (muscle-invasive), where treatment is more complex and outcomes are less good.

Kidney cancer accounts for around 3 per cent of cancer diagnoses in Ireland. The most common type is renal cell carcinoma. Many kidney cancers are now detected incidentally on imaging done for other reasons (such as an ultrasound or CT scan for abdominal pain or another investigation), but a significant minority present with visible haematuria, flank pain, or a palpable mass. Risk factors include smoking, obesity, hypertension, advanced kidney disease, and certain inherited conditions. The outlook depends on the stage at diagnosis. Localised kidney cancers detected early have a good prognosis with surgery. More advanced disease is more difficult to treat, although recent advances in immunotherapy and targeted therapy have improved outcomes significantly.

Prostate cancer occasionally presents with haematuria, particularly when locally advanced. More commonly, it is identified through PSA testing or causes urinary symptoms. It is the most common cancer in men in Ireland, but only a small minority present with haematuria as the initial symptom.

Upper urinary tract urothelial cancer (cancer of the lining of the ureters or renal pelvis) is rare but important. It is most often associated with a history of bladder cancer or with certain occupational exposures. It typically presents with visible haematuria. Imaging (usually CT urogram) is the standard investigation.

Which patients are at highest risk? Age over 40 (and particularly over 60) increases risk substantially. Current or former smoking is a major factor for bladder and kidney cancer. Occupational exposure to certain chemicals raises bladder cancer risk. Family history of urological cancer matters less than for some other cancers but is still relevant. Pelvic radiation history increases bladder cancer risk. Cyclophosphamide exposure (used in some chemotherapy and immunosuppression regimens) increases bladder cancer risk for decades.

The pattern of haematuria matters. Visible haematuria carries a higher risk of cancer than non-visible haematuria. Painless visible haematuria in an older patient is the classical presentation of bladder cancer. Haematuria with pain is more often associated with infection or kidney stones, although it can occur with cancer too. Haematuria with weight loss or other systemic symptoms raises particular concern.

The standard assessment of haematuria with concern for cancer includes several elements. A urine sample is checked for infection, blood, and protein. Cytology (looking for cancer cells in the urine) is sometimes added, particularly for high-risk patients. Imaging of the kidneys and ureters is done, with CT urogram being the most sensitive test, although ultrasound is sometimes used as an initial screen. Cystoscopy, which involves direct visualisation of the inside of the bladder with a flexible telescope, is performed by a urologist. Cystoscopy is the gold standard for excluding bladder cancer and cannot be replaced by imaging.

The sequence and combination of investigations vary by local practice and by the individual patient’s risk profile. The general principle is that visible haematuria warrants more rapid and complete investigation than non-visible haematuria, particularly in older patients or those with risk factors.

If no cause is found after thorough investigation, follow-up is usually recommended. Repeat assessment at 6 to 12 months catches any cancers that may have been missed at the first investigation. Persistent non-visible haematuria over years, with negative urological investigations, often turns out to be benign (such as thin basement membrane disease or mild IgA nephropathy), but ongoing monitoring is sensible.

The role of nephrology in patients with haematuria is distinct from the urological role. Urology investigates for bladder, kidney, prostate, and ureteric structural causes. Nephrology investigates for medical causes affecting the kidney filters themselves, particularly glomerulonephritis. The combination of haematuria and proteinuria, especially with reduced kidney function, raises the possibility of glomerular disease and warrants nephrology assessment, sometimes including kidney biopsy. The conditions to consider include IgA nephropathy, thin basement membrane disease, Alport syndrome, post-infectious glomerulonephritis, and various forms of vasculitis.

For patients, the practical messages are clear. Visible blood in urine should never be ignored, even if it occurs only once and clears up quickly. The investigation is straightforward, the vast majority of results are reassuring, and for the small number where something more serious is found, early detection makes a substantial difference to outcomes. Non-visible blood in urine found on a routine dipstick is less urgent but still warrants investigation, particularly in those over 40 or with risk factors. Persistent non-visible haematuria with no identified cause may need ongoing monitoring even if the initial investigation is reassuring.

If you have noticed visible blood in your urine or have been told you have persistent non-visible haematuria, see your GP for assessment. They can arrange the appropriate initial investigations and referral to urology or nephrology depending on the pattern of findings. The earlier the assessment, the better the long-term outcomes for any underlying cause.

I see private patients at Blackrock Clinic, The Beacon Hospital, Bon Secours Dublin, the Hermitage Medical Centre, and St Vincent’s Private Hospital. If you would like a consultation about your kidney health, you or your GP can contact my secretary through drrorymcquillan.ie. Most patients are seen within two to three weeks of referral.